



Published in final edited form as:

Horm Behav. 2013 February ; 63(2): 284–290. doi:10.1016/j.yhbeh.2012.06.003.

Progesterone and Neuroprotection

Meharvan Singh and Chang Su

Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer's Disease Research, Center FOR HER, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107 USA;

Summary

Numerous studies aimed at identifying the role of estrogen on the brain have used the ovariectomized rodent as the experimental model. And while estrogen intervention in these animals have, at least partially, restored cholinergic, neurotrophin and cognitive deficits seen in the ovariectomized animal, it is worth considering that the removal of the ovaries results in the loss of not only circulating estrogen but of circulating progesterone as well. As such, the various deficits associated with ovariectomy may be attributed to the loss of progesterone as well. Similarly, one must also consider the fact that the human menopause results in the precipitous decline of not just circulating estrogens, but in circulating progesterone as well and as such, the increased risk for diseases such as Alzheimer's disease during the postmenopausal period could also be contributed by this loss of progesterone. In fact, progesterone has been shown to exert neuroprotective effects, both in cell models, animal models and in humans. Here, we review the evidence that supports the neuroprotective effects of progesterone and discuss the various mechanisms that are thought to mediate these protective effects. We also discuss the receptor pharmacology of progesterone's neuroprotective effects and present a conceptual model of progesterone action that supports the complementary effects of membrane-associated and classical intracellular progesterone receptors. In addition, we discuss fundamental differences in the neurobiology of progesterone and the clinically used, synthetic progestin, medroxyprogesterone acetate that may offer an explanation for the negative findings of the combined estrogen/progestin arm of the Women's Health Initiative-Memory Study (WHIMS) and suggest that the type of progestin used may dictate the outcome of either pre-clinical or clinical studies that addresses brain function.

The Biology of Progesterone

Progesterone, the natural progestin, is a major gonadal hormone that is synthesized primarily by the ovary in the female, and the testes and adrenal cortex in the male. While progesterone levels are generally higher in the female, it is worth noting that levels of progesterone during the female follicular phase of the menstrual cycle are similar to those seen in males (Strauss and Barbieri, 2004), and thus, may be equally important in males. The "classical" mechanism by which progesterone elicits its effects is via the progesterone receptor (PR), which like the estrogen receptor (ER), has classically been described as a nuclear

© 2012 Elsevier Inc. All rights reserved.

Corresponding Author: Meharvan Singh, Ph.D. Department of Pharmacology and Neuroscience University of North Texas Health Science Center at Fort Worth 3500 Camp Bowie Blvd. Fort Worth, TX 76107 Phone: 817-735-5429 FAX: 817-735-0179 meharvan.singh@unthsc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

transcription factor, acting through specific progesterone response elements (PRE) within the promoter region of target genes to regulate transcription. These progesterone receptors are widely distributed in the developing and adult brain (see (Kato et al., 1994; MacLusky and McEwen, 1980) for review), and as such, supports various brain regions as normal targets of progesterone. Two major isoforms of the classical progesterone receptor exist, PR-B, and its N-terminally truncated form, PR-A [for review, see (Conneely and Lydon, 2000)]. The latter has been shown to exert negative control of not only PR-B-mediated transcription, but that mediated by the ER and glucocorticoid receptor as well (Vegeto et al., 1993). This negative regulation of ER function by a PR may underlie, at least in part, the mechanism by which progestins functionally antagonize the effects of estrogen. For example, progesterone can inhibit estrogen's ability to increase serum levels of 1, 25, dihydroxy vitamin D (Bikle et al., 1992), whose consequence may be to antagonize estrogen's beneficial effects on the bone. Relevant to hormone therapy, the functional antagonism exerted by progestins on estrogen's actions also underlie the rationale for combined estrogen and progestin therapy in women with an intact uterus, as the addition of a progestin reduces the risk of uterine cancer associated with un-opposed estrogen therapy (Hirvonen, 1996). However, the relationship between progesterone and estrogen receptors may not always be antagonistic. For example, Migliaccio et al., demonstrated not only a physical interaction of the progesterone receptor with the estrogen receptor, but that this association was necessary for progesterone to elicit the activation of a signal transduction pathway, the mitogen activated protein kinase (MAPK) pathway, in mammary tumor cells (Migliaccio et al., 1998).

In addition to the regulation of gene transcription, progesterone can also elicit its effects via non-genomic mechanisms such as through the activation of signal transduction pathways. Among those second messenger/signal transduction systems now known to be activated by progesterone include cAMP/PKA (Collado et al., 1985), MAPK (ERK1/2) (Migliaccio et al., 1998; Singh, 2001) and the PI-3K/Akt pathway (Singh, 2001). Activation of such signaling pathways has, in fact, been implicated in its neuroprotective effects (see below).

Progesterone-induced neuroprotection

Progesterone has been reported to exert protective effects in a variety of experimental models that mimic certain pathogenic aspects of brain dysfunction seen with advanced age- or age-related neurodegenerative diseases such as Alzheimer's disease. For example, physiologically relevant concentrations of progesterone have been shown to significantly attenuate oxidative injury resulting from glutamate (Kaur et al., 2007; Nilsen and Brinton, 2002a, b, 2003) and glucose deprivation-induced toxicity (Goodman et al., 1996), and also protects against FeSO₄- and amyloid β -peptide - induced toxicity in primary hippocampal cultures (Goodman et al., 1996).

Progesterone is also an effective neuroprotectant in animal models of stroke. For example, Jiang *et al.* illustrated that the administration of progesterone before middle cerebral artery occlusion (MCAO) resulted in a marked reduction in cerebral infarction and reduced impairments that resulted from the occlusion (Jiang et al., 1996). Interestingly, post-ischemic administration of progesterone was also found to be protective (Kumon et al., 2000; Morali et al., 2005), and resulted in improvements in various functional measures, including the rotarod test, and adhesive-backed somatosensory and neurological scores (Chen et al., 1999). The ability of progesterone to protect even when administered after the insult (albeit within a relatively narrow window) may suggest that both rapid/immediate and long-term mechanisms of progesterone action are involved in the protective effects of progesterone. Progesterone has also been shown to reduce the amount of cell death following an acute episode of global ischemia (Cervantes et al., 2002), and is thought to be related to the ability of progesterone to reduce lipid peroxidation, the generation of

isoprostanes (Roof et al., 1997) and the expression of pro-inflammatory genes (Pettus et al., 2005). It is worth pointing out that in these studies, the dose of progesterone used may also be relevant since supraphysiological serum/plasma levels of progesterone were achieved. With such doses, the resulting levels of allopregnanolone, the major progesterone metabolite, could underlie some of the neuroprotective levels (see below for discussion of allopregnanolone and neuroprotection).

Another model in which progesterone has been shown to exert protective effects is in the traumatic brain injury (TBI) model. The administration of progesterone reduces cerebral edema for up to 24 hours after injury. In a rodent model of medial frontal cortex impact injury, progesterone reduced complement factor C3, glial fibrillary acidic protein (GFAP), (Pettus et al., 2005), all of which can be interpreted as protective mechanisms. Progesterone also decreased the levels of lipid peroxidation in male rats when administered after TBI (Roof and Hall, 2000).

Interestingly, there appears to be a sex difference in terms of the severity of impairment following TBI. Females appeared to have less spatial learning impairments when compared to their male counterparts. And though the lesion size was similar, females exhibited less ventricular dilation indicating lower edema and water retention (Attella et al., 1987). In fact, direct assessments of edema reveal that progesterone treatment significantly attenuates the level of edema seen in injured animals in contrast to non-progesterone treated animals that had undergone experimental TBI (Roof et al., 1996).

The protective effects of progesterone are also evident in other regions of the central nervous system in addition to the hippocampus and cerebral cortex. For example, progesterone has also been shown to have a beneficial effect on spinal cord contusion injuries as supported by the work of Thomas *et al.* who found that there was a marked reduction in the size of the lesion and a prevention of secondary neuronal loss with progesterone treatment (Thomas et al., 1999). Further support for progesterone's protective actions in the spinal cord comes from the observation that progesterone has been shown to promote morphological and functional recovery in the Wobbler mouse, an animal model of spinal cord degeneration (Gonzalez Deniselle et al., 2002a; Gonzalez Deniselle et al., 2002b). Progesterone can also induce re-myelination as supported by the increased expression of myelin proteins in the damaged sciatic nerves of both young adult rats and in 22-24-month-old males (Ibanez et al., 2003). Thus, progesterone may be of potential therapeutic benefit in diseases where demyelination is an important component of its pathogenesis.

While the studies described above were all derived from animal models and cell/tissue culture models, it is worth mentioning that a relatively recently completed phase II, randomized, double-blind, placebo-controlled clinical trial assessing the efficacy of progesterone treatment for acute traumatic brain injury yielded promising results. The data suggested that progesterone treatment can improve functional recovery, at least when administered to those who experienced moderate, but not severe, traumatic brain injury (Junpeng et al., 2011; Vandromme et al., 2008; Wali et al., 2011; Wright et al., 2007; Xiao et al., 2008).

While several studies have suggested that progesterone does not interfere with the beneficial effects of estrogens (E2) (Lorenz et al., 2009; Mannella et al., 2009; Nilsen and Brinton, 2002b), other studies have shown that progesterone or synthetic progestin antagonizes the protective effects of estrogen (Aguirre et al., 2010; Aguirre and Baudry, 2009; Carroll et al., 2008; Jayaraman and Pike, 2009; Rosario et al., 2006; Yao et al., 2011). For example, Murphy and Segal demonstrated that progesterone antagonizes the effect of E2 on

hippocampal spine density (Murphy and Segal, 2000). In addition, McEwen and Woolley showed that in adult as well as in developing brain, progesterone contributed to the loss of hippocampal spines and spine synapses noted across the estrous cycle (McEwen and Woolley, 1994), although progesterone did result initially (within the first 6 hours) in an increase in hippocampal dendritic spine density (Woolley and McEwen, 1993). In contrast, Zhu *et al.* reported a positive influence of progesterone similar to that of E2 on synaptogenesis in the hippocampus of a rat stroke model (Zhao *et al.*, 2011), and Foy *et al.* (Foy *et al.*, 2008) demonstrated that progesterone enhanced LTP and LTD in rat hippocampus. Future studies will undoubtedly clarify the biological basis of this apparent discrepancy, which could include the experimental model being used (reflecting the types of receptors expressed in the model), the concentrations/doses of progesterone used, timing of the progesterone relative to that of estrogen, the timing of progesterone relative to the insult, and even potential regional differences in the effects of combined estrogen and progesterone.

Mechanisms underlying progesterone's protective effects

Numerous mechanisms of action likely underlie the protective effects of progesterone. The classical genomic mechanism of progesterone action, for example, may be involved in the regulation of neurotrophin expression (Kaur *et al.*, 2007), which in turn, could promote cell survival. Alternatively, progesterone may act through novel receptor systems, such as the membrane PR or the sigma receptor (another putative receptor for progesterone), to activate certain signal transduction pathways, which in turn, triggers cellular events that are relevant and important for neuroprotection. Additionally, major metabolites of progesterone, such as allopregnanolone, have been reported to participate in the neuroprotective effects of progesterone (Ciriza *et al.*, 2004).

With regards to the relationship between progesterone and neurotrophins, we (Kaur *et al.*, 2007; Singh *et al.*, 1995) and others (Gonzalez Deniselle *et al.*, 2007; Gonzalez *et al.*, 2004; Sohrabji *et al.*, 1995) have shown that steroid hormones, including progesterone, increase the expression of BDNF. Further, we found that neurotrophin signaling was necessary for progesterone induced protection (Jodhka *et al.*, 2009).

With respect to “non-genomic” or cell signaling mechanisms underlying progesterone's protective effects, progesterone has been shown to elicit rapid effects on specific signaling pathways including the cAMP/PKA (Collado *et al.*, 1985), MAPK (ERK1/2) (Migliaccio *et al.*, 1998; Nilsen and Brinton, 2002b; Singh, 2001) and the PI-3K/Akt pathway (Singh, 2001), all of which have been implicated in mediating neuroprotective effects. Progesterone-induced neuroprotection has not only been correlated with activation of the MAPK and Akt signaling pathways (Nilsen and Brinton, 2002b, 2003) but has also been shown to depend on the activation of the MAPK pathway (Kaur *et al.*, 2007). Activation of these signaling pathways, in turn, may also lead to increased expression of anti-apoptotic proteins such as Bcl-2 (Nilsen and Brinton, 2002b).

Another mechanism by which progesterone can exert protective effects is through its metabolites, which in turn, can interact with membrane-associated receptors coupled to ion-channels, such as the GABA_A receptor system (see (Deutsch *et al.*, 1992) for review). Such metabolites include allopregnanolone (or 3 α , 5 α tetrahydroprogesterone), which bind to discrete sites within the hydrophobic domain of the GABA_A receptor complex, and result in the potentiation of GABA-induced chloride conductance. Indeed, allopregnanolone has been suggested to play a role in mediating the protective effects of progesterone (Ardeshiri *et al.*, 2006; Djebaili *et al.*, 2004; He *et al.*, 2004a; He *et al.*, 2004b; Sayeed *et al.*, 2009; Vitarbo *et al.*, 2004). In addition to the effects of allopregnanolone on the GABA_A receptor, as outlined

above, allopregnanolone may also elicit its protective effects through its actions on the mitochondria (Robertson et al., 2006). For example, allopregnanolone was reported to inhibit currents associated with the opening of the mitochondrial permeability transition pore (mtPTP) (Sayeed et al., 2009), and as such, may help reduce the potential apoptotic consequences of mtPTP opening (such as cytochrome c release) during insult or injury.

In addition to the allosteric effects described above, progesterone itself may have non-allosteric influences on the GABA_A receptor. Progesterone may influence the GABA_A receptor via the activation of a signal transduction pathway, which in turn, influences GABA-gated currents through phosphorylation of discrete sites within certain subunits of the GABA_A receptor (Bell-Horner et al., 2006; Vasan et al., 2003). Since the regulation of the GABA_A receptor has been shown to modulate cell survival, particularly in models of excitotoxicity, the regulation of the GABA_A receptor by progesterone may be relevant to the protective effect of progesterone seen against kainate-induced seizure activity and subsequent cell death (Hoffman et al., 2003).

Progesterone and cognitive function

When considering the ovariectomized animal, it is important to recognize that this surgical intervention results in the loss of not just estradiol, but of progesterone as well. As such, the cognitive deficits we and others have observed following ovariectomy may have been contributed by the loss of circulating progesterone as well. And though numerous studies, including those from our laboratory, have clearly described the neuroprotective effects of progesterone against a wide array of insults and injuries (see above), the effect of progesterone alone on cognitive function is considerably less well studied and understood. Moreover, interpretation of the data from the WHI that described an accelerated decline in cognitive function in the estrogen plus progestin treated group is complicated by the fact that the effects of progestins on learning and memory is poorly understood.

Those studies that have assessed progesterone's effects on cognitive function have generally done so within the context of an injury, such as traumatic brain injury (Roof et al., 1997), or in experimental models of accelerated neurodegeneration and/or cognitive impairment such as in the triple transgenic mouse model of Alzheimer's disease (3xTg-AD) (Carroll et al., 2007), or the scopolamine-induced memory impairment model (Tanabe et al., 2004). In these models, progesterone helps to preserve cognitive performance. There are, however, a few studies that have described the effects of progesterone on cognitive function in ovariectomized rodents. Frye and colleagues (Frye et al., 2007) described a beneficial effect of progesterone in an object placement task relative to ovariectomized controls. Interestingly, as seen with estradiol, the effectiveness of progesterone required that progesterone be administered within a specific window following "training", suggesting that the effectiveness of progesterone may be dependent on time (or age). Mechanistically, progesterone may either directly, or indirectly through the regulation of BDNF (see above) activate signaling pathways, such as the ERK/MAPK and PI3K/Akt pathways which, in turn, can regulate LTP (long-term potentiation), the synaptic substrate for learning and memory (Chen et al., 2006; Xu et al., 2006; Ying et al., 2002).

In contrast to the beneficial effect of progesterone reported, Chesler and Juraska (Chesler and Juraska, 2000) described that progesterone administration to ovariectomized rats had no effect on spatial learning relative to their age-matched and non-hormone treated ovariectomized controls. Quite interestingly, studies from one laboratory have described that ovariectomy of aged rats does not impair spatial memory, but rather enhances it (Bimonte-Nelson et al., 2003; Bimonte-Nelson et al., 2004). And further, progesterone counteracted the beneficial effects of ovariectomy. It is worth pointing out, however, that the aged

Fisher-344 rats in these studies were likely pseudopregnant, having elevated progesterone levels (and low estradiol levels). In fact, the elevated levels of progesterone during pseudopregnant estropause have been implicated in the impaired spatial cognitive performance of these rats (Warren and Juraska, 2000). Overall, these studies underscore the complexity by which progesterone may influence cognitive function as a function of age, and at the very least, suggest that additional studies are required to better understand the consequences of progesterone on cognitive function, throughout the lifespan.

Receptor pharmacology of progesterone's protective effects

It is clear that the classical, intracellular/nuclear PR certainly plays an important role in mediating the effects of progesterone. For example, our laboratory has determined that the ability of progesterone to increase the expression (mRNA and protein levels) of brain-derived neurotrophic factor (BDNF), a key mediator of progesterone's protective effects, requires the classical PR (Jodhka et al., 2009). Further, Cai and colleagues (Cai et al., 2008) have implicated the classical/intracellular PR in the protective effects of progesterone against an experimental model (middle cerebral artery occlusion) of stroke. More recently, Liu et al., describe the key role of the classical PR in neuroprotection after experimental stroke (Liu et al., 2012), using the PR knockout model. This experimental model (at least the homozygous knockout) has clear reproductive behavior deficits (Conneely and Lydon, 2000), but does not appear to, in and of itself, result in overt phenotypic changes in brain morphology.

However, evidence also exists for alternative mechanisms of action, including that which involves integral membrane progesterone receptors. For example, the effect of progesterone has been reported in the brain of PR knock-out (PRKO) mice (Krebs et al., 2000), suggesting PRs other than the classical PR may mediate the effect of progesterone in the CNS. In fact, several lines of evidence recently obtained suggest that the rapid effects of progesterone are mediated by cell membrane-associated PRs expressed in the brain (Balasubramanian et al., 2008a, b; Liu et al., 2009; Tokmakov and Fukami, 2009). If nothing else, progesterone's high degree of lipophilicity (having a logP value, or octanol/water partition coefficient, of approximately 4), may be consistent with the idea that progesterone interacts with a plasma membrane associated receptor.

Membrane receptors for progesterone, though proposed for many years based on the existence of specific, displaceable binding sites observed in synaptosomal membrane preparations (Ke and Ramirez, 1990; Towle and Sze, 1983), have only recently been cloned. For example, Zhu and colleagues discovered a novel membrane-associated progesterone receptor, termed mPR (Zhu et al., 2003a), that has a predicted seven transmembrane-spanning domain, and is coupled to the $G_{i/o}$ class of G-proteins (Zhu et al., 2003b). Other membrane progesterone receptors include 25-Dx (also called Pgrmc1), an apparently neuron-specific membrane progesterone receptor (Falkenstein et al., 1998; Krebs et al., 2000; Meyer et al., 1996), that is involved in numerous aspects of cell function, ranging from neuronal development (Sakamoto et al., 2004), steroidogenesis (Min et al., 2004), regulation of CSF production and osmoregulation (Meffre et al., 2005), and the regulation of reproductive behavior (Krebs et al., 2000). Though our laboratory has determined that the classical PR, mPR α , mPR β and Pgrmc1 are expressed in our experimental models of the CNS wherein we have shown progesterone-induced neuroprotection, we have recently determined that while progesterone's ability to increase BDNF expression is dependent on the classical PR (Jodhka et al., 2009), it is the membrane associated receptor, Pgrmc1, that mediates the effect of progesterone on BDNF release. Further, this effect on BDNF release appears to be mediated by ERK5 (Su and Singh, unpublished observations). Collectively, we believe that these effects on BDNF are critical to progesterone's neuroprotective capacity

(Kaur et al., 2007). Moreover, a putative ligand of membrane associated progesterone receptors, the BSA-conjugated progesterone (P4-BSA), that does not bind to the intracellular localized classical PR, fails to increase BDNF levels but yet, is effective in increasing the phosphorylation of ERK1/2 (Jodhka et al., 2009), another proposed mediator of progesterone's neuroprotective effects (Kaur et al., 2007). As such, the ability of a progestin to have maximal neuroprotective efficacy may depend on the complement of progesterone receptors that it is capable of binding/activating.

And finally, progesterone has also been found to interact with sigma 1 (σ_1) receptor (Selmin et al., 1996; Seth et al., 1998). Given the reported role of the sigma 1 receptor in neuroprotection (for review, see (Maurice et al., 2006)), this mechanism may also be relevant to progesterone's protective actions.

Why the type of progestin matters

It is estimated that by 2010, the population of women between the ages of 45 and 64 will reach approximately 42 million (U.S. Census Bureau. Projected population of the United States, by Age and Sex: 200 to 2050. www.census.gov/ipc/www/usinterimproj/ Internet release date: March 18, 2004). Among the health-related changes and decisions these women will need to consider include whether or not to consider the use of hormone therapy for not just the management of menopausal symptoms, but potentially, to help maintain a healthy brain. And though numerous basic science, epidemiological and some clinical studies have supported the potential benefit of hormone therapy in reducing the incidence of age-associated brain dysfunction (including reducing the risk for Alzheimer's disease), recent results from the Women's Health Initiative-Memory Study (WHIMS) failed to reveal beneficial effects in reducing the risk of Alzheimer's disease or "all-cause" dementia. As a consequence, these reports left the field unsettled as to the future of hormone therapy. Since the publication of these studies, it became apparent that there were important caveats to the data that needed to be considered. Among these included consideration of the type of hormone used. Indeed there are important differences in the neurobiology of two major progestins, the "natural" progestin, progesterone, and the synthetic medroxyprogesterone acetate (MPA), the most commonly used progestin in hormone therapy regimens.

Medroxyprogesterone acetate (MPA), a synthetic progestin derived from 17 α -hydroxyprogesterone, is often used in conjunction with estrogens to reduce the risk of certain cancers (cervical cancer, for example) resulting from unopposed estrogen therapy (Gambrell, 1986; Hirvonen, 1996). First, though both progesterone and MPA can bind to the classical PR, it is important to recognize that there are important pharmacological and pharmacokinetic differences between MPA and progesterone. For example, orally administered MPA does not undergo any first pass effects (Schindler et al., 2003), unlike progesterone. Furthermore, MPA has little binding affinity for sex hormone binding globulin (Schindler et al., 2003). In addition to differences in bioavailability and half-life, MPA also displays many non-progestagenic effects (Schindler et al., 2003), including the ability to bind to the androgen receptor (AR) where it acts as a partial agonist (Winneker et al., 2003) with a binding affinity (Kd) of approximately 2.1 nM (Hackenberg et al., 1990). Progesterone, in contrast, does not bind to the AR (Schindler et al., 2003). MPA can also bind to, and activate, glucocorticoid receptors (Koubovec et al., 2005; Schindler et al., 2003) with an effective concentration (EC50) that is nearly 300-fold lower than that for progesterone (Koubovec et al., 2005).

While progesterone and MPA may be equally effective at reducing the uterotrophic effects of un-opposed estrogen treatment, their effects on the brain are far from identical. In fact, it has become increasingly clear that while progesterone is neuroprotective, MPA is not. For

example, our laboratory described that in cerebral cortical explants, the difference in neuroprotective efficacy between progesterone and MPA may have been attributed to their differential regulation of BDNF. Specifically, while progesterone increased both the mRNA and protein levels of BDNF in the cerebral cortex, MPA treatment resulted in a substantial inhibition (Jodhka et al., 2009). Combined with the observation that progesterone's protective effects may be dependent on neurotrophin signaling (Kaur et al., 2007), this inhibition of BDNF expression by MPA may not just be without effect, but may actually have adverse consequences to brain function. Similarly, the Brinton laboratory has shown in hippocampal cultures that while progesterone is protective, MPA is not. In this model, the protective effects of progesterone appeared to be mediated, in part, by attenuating the glutamate-induced increase in intracellular Ca^{2+} levels. MPA, in contrast, failed to alter the glutamate-induced influx of Ca^{2+} . Of significance was that MPA not only failed to elicit protective effects, but also blocked the beneficial effect of estradiol. In sharp contrast, progesterone did not inhibit the effect of estradiol (Nilsen and Brinton, 2002a). Furthermore, while some of the neuroprotective effects of progesterone are mediated by its neuroactive metabolite, allopregnanolone (see discussion above), it is unclear if MPA is a substrate for the progesterone metabolizing enzymes 5 α -reductase and 3 α -hydroxysteroid dehydrogenase. Instead, MPA has been shown to inhibit the biosynthetic enzymes associated with the conversion of progesterone to allopregnanolone. Thus, both the inability of MPA to be converted to neuroactive steroid metabolites in conjunction with its effect in reducing potential conversion of progesterone to allopregnanolone may contribute to its lack of neuroprotection.

As stated above, progesterone's protective effects, in at least two neuronal models (cerebral cortical neurons and hippocampal neurons), was dependent on activation of the ERK/MAPK pathway (Kaur et al., 2007; Nilsen and Brinton, 2002a, 2003). While both progesterone and MPA can elicit ERK phosphorylation, only progesterone treatment resulted in nuclear translocation of ERK (Nilsen and Brinton, 2003), the consequence of which is likely to regulate key genes, whose protein products may enable more long term/sustainable protection. In fact, progesterone, but not MPA, increased the expression of the anti-apoptotic Bcl-2 protein. And as observed in the model of glutamate-induced Ca^{2+} influx, MPA not only failed to increase expression of Bcl-2, but actually inhibited that elicited by estradiol (Nilsen and Brinton, 2002a).

The disparity between the effects of progesterone and MPA has also been observed *in vivo*. For example, a study using rhesus monkeys illustrated that combined treatment with estradiol and progesterone protects against coronary vasospasm, whereas estradiol + MPA treatment did not (Miyagawa et al., 1997). And once again, in contrast to the antagonistic effects of MPA on estrogen's effects, progesterone enhanced the protective effects of estrogen against exercise-induced myocardial ischemia in post-menopausal women to, whereas MPA did not (Rosano et al., 2000). Moreover, in a model of stroke (reversible focal stroke using the intraluminal filament model followed by 22 hours of reperfusion), MPA diminished the protective effects of conjugated equine estrogens (CEE) and MPA diminished estrogen's ability to reduce stroke damage. The functional antagonistic effects of MPA were also noted in the cholinergic system of monkeys, where MPA administered in conjunction with CEE reduced choline acetyl transferase (ChAT) in such cognition-relevant areas of the brain as the medial septum (Gibbs et al., 2002). Similar consequences of MPA were seen in the cardiovascular system of cynomolgus monkeys. Adams *et al.*, demonstrated that monkeys treated with CEE showed a 72% reduction in coronary artery atherosclerosis whereas there were no benefits observed in CEE plus MPA group (Adams et al., 1997). Interestingly, with regards to the traumatic brain injury model, MPA required a larger dose than progesterone to accomplish a comparable reduction in cerebral edema. However regardless of the dose of MPA, MPA did not favor a better behavioral recovery than

progesterone (reviewed in (Stein, 2005)). A summary of the comparison between the potentially neuroprotection-relevant effects of progesterone and MPA are provided in Table 1.

Collectively, the information presented here supports the conclusion that progesterone is protective and that such protection can be afforded through multiple mechanisms. In addition, the data from several laboratories support the conclusion that not all progestins are created equal, particularly within the context of neuroprotection. Such differences may be important in considering the results of the WHIMS studies which used MPA rather than progesterone, and further, could provide critical insight into the development of the most effective therapeutic formulations for the treatment of the menopause and various diseases whose incidence increases during the post-menopausal period.

Abbreviations

| | |
|-------------|---------------------------------------|
| MPA | medroxyprogesterone acetate |
| PR | progesterone receptor |
| AR | androgen receptor |
| GR | glucocorticoid receptor |
| ERK | extracellular-signal regulated kinase |
| P4 | progesterone |
| BDNF | brain-derived neurotrophic factor |

REFERENCES

- Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol.* 1997; 17:217–221. [PubMed: 9012659]
- Aguirre C, Jayaraman A, Pike C, Baudry M. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. *J Neurochem.* 2010; 115:1277–1287. [PubMed: 20977477]
- Aguirre CC, Baudry M. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. *Eur J Neurosci.* 2009; 29:447–454. [PubMed: 19175406]
- Ardeshiri A, Kelley MH, Korner IP, Hurn PD, Herson PS. Mechanism of progesterone neuroprotection of rat cerebellar Purkinje cells following oxygen-glucose deprivation. *Eur J Neurosci.* 2006; 24:2567–2574. [PubMed: 17100844]
- Attella MJ, Nattinville A, Stein DG. Hormonal state affects recovery from frontal cortex lesions in adult female rats. *Behav Neural Biol.* 1987; 48:352–367. [PubMed: 3689284]
- Balasubramanian B, Portillo W, Reyna A, Chen JZ, Moore AN, Dash PK, Mani SK. Nonclassical mechanisms of progesterone action in the brain: I. Protein kinase C activation in the hypothalamus of female rats. *Endocrinology.* 2008a; 149:5509–5517. [PubMed: 18617608]
- Balasubramanian B, Portillo W, Reyna A, Chen JZ, Moore AN, Dash PK, Mani SK. Nonclassical mechanisms of progesterone action in the brain: II. Role of calmodulin-dependent protein kinase II in progesterone-mediated signaling in the hypothalamus of female rats. *Endocrinology.* 2008b; 149:5518–5526. [PubMed: 18617607]
- Bell-Horner CL, Dohi A, Nguyen Q, Dillon GH, Singh M. ERK/MAPK pathway regulates GABAA receptors. *J Neurobiol.* 2006; 66:1467–1474. [PubMed: 17013930]
- Bikle DD, Halloran BP, Harris ST, Portale AA. Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. *J Clin Endocrinol Metab.* 1992; 75:519–523. [PubMed: 1639954]

- Bimonte-Nelson HA, Singleton RS, Hunter CL, Price KL, Moore AB, Granholm AC. Ovarian hormones and cognition in the aged female rat: I. Long-term, but not short-term, ovariectomy enhances spatial performance. *Behav Neurosci.* 2003; 117:1395–1406. [PubMed: 14674857]
- Bimonte-Nelson HA, Singleton RS, Williams BJ, Granholm AC. Ovarian hormones and cognition in the aged female rat: II. progesterone supplementation reverses the cognitive enhancing effects of ovariectomy. *Behav Neurosci.* 2004; 118:707–714. [PubMed: 15301598]
- Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. *Neuropharmacology.* 2008; 55:127–138. [PubMed: 18572204]
- Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. *J Neurosci.* 2007; 27:13357–13365. [PubMed: 18045930]
- Carroll JC, Rosario ER, Pike CJ. Progesterone blocks estrogen neuroprotection from kainate in middle-aged female rats. *Neurosci Lett.* 2008; 445:229–232. [PubMed: 18790007]
- Cervantes M, Gonzalez-Vidal MD, Ruelas R, Escobar A, Morali G. Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus. *Arch Med Res.* 2002; 33:6–14. [PubMed: 11825624]
- Chen J, Chopp M, Li Y. Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat. *J Neurol Sci.* 1999; 171:24–30. [PubMed: 10567046]
- Chen L, Miyamoto Y, Furuya K, Dai XN, Mori N, Sokabe M. Chronic DHEAS administration facilitates hippocampal long-term potentiation via an amplification of Src-dependent NMDA receptor signaling. *Neuropharmacology.* 2006; 51:659–670. [PubMed: 16806295]
- Chesler EJ, Juraska JM. Acute administration of estrogen and progesterone impairs the acquisition of the spatial morris water maze in ovariectomized rats. *Horm Behav.* 2000; 38:234–242. [PubMed: 11104641]
- Ciriza I, Azcoitia I, Garcia-Segura LM. Reduced progesterone metabolites protect rat hippocampal neurons from kainic acid excitotoxicity in vivo. *J Neuroendocrinol.* 2004; 16:58–63. [PubMed: 14962077]
- Collado ML, Rodriguez-Manzo G, Cruz ML. Effect of progesterone upon adenylate cyclase activity and cAMP levels on brain areas. *Pharmacol Biochem Behav.* 1985; 23:501–504. [PubMed: 2999831]
- Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. *Steroids.* 2000; 65:571–577. [PubMed: 11108861]
- Deutsch SI, Mastropaolo J, Hitri A. GABA-active steroids: endogenous modulators of GABA-gated chloride ion conductance. *Clin Neuropharmacol.* 1992; 15:352–364. [PubMed: 1330306]
- Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. *Neuroscience.* 2004; 123:349–359. [PubMed: 14698743]
- Falkenstein E, Schmieding K, Lange A, Meyer C, Gerdes D, Welsch U, Wehling M. Localization of a putative progesterone membrane binding protein in porcine hepatocytes. *Cell Mol Biol (Noisy-le-grand).* 1998; 44:571–578. [PubMed: 9678891]
- Foy MR, Akopian G, Thompson RF. Progesterone regulation of synaptic transmission and plasticity in rodent hippocampus. *Learn Mem.* 2008; 15:820–822. [PubMed: 18984562]
- Frye CA, Duffy CK, Walf AA. Estrogens and progestins enhance spatial learning of intact and ovariectomized rats in the object placement task. *Neurobiol Learn Mem.* 2007; 88:208–216. [PubMed: 17507257]
- Gambrell RD Jr. The role of hormones in the etiology and prevention of endometrial cancer. *Clin Obstet Gynaecol.* 1986; 13:695–723. [PubMed: 3791826]
- Gibbs RB, Nelson D, Anthony MS, Clarkson TB. Effects of long-term hormone replacement and of tibolone on choline acetyltransferase and acetylcholinesterase activities in the brains of ovariectomized, cynomolgus monkeys. *Neuroscience.* 2002; 113:907–914. [PubMed: 12182896]
- Gonzalez Deniselle MC, Garay L, Gonzalez S, Saravia F, Labombarda F, Guennoun R, Schumacher M, De Nicola AF. Progesterone modulates brain-derived neurotrophic factor and choline

acetyltransferase in degenerating Wobbler motoneurons. *Exp Neurol.* 2007; 203:406–414. [PubMed: 17052708]

- Gonzalez Deniselle MC, Lopez Costa JJ, Gonzalez SL, Labombarda F, Garay L, Guennoun R, Schumacher M, De Nicola AF. Basis of progesterone protection in spinal cord neurodegeneration. *J Steroid Biochem Mol Biol.* 2002a; 83:199–209. [PubMed: 12650717]
- Gonzalez Deniselle MC, Lopez-Costa JJ, Saavedra JP, Pietranera L, Gonzalez SL, Garay L, Guennoun R, Schumacher M, De Nicola AF. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. *Neurobiol Dis.* 2002b; 11:457–468. [PubMed: 12586554]
- Gonzalez SL, Labombarda F, Gonzalez Deniselle MC, Guennoun R, Schumacher M, De Nicola AF. Progesterone up-regulates neuronal brain-derived neurotrophic factor expression in the injured spinal cord. *Neuroscience.* 2004; 125:605–614. [PubMed: 15099674]
- Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. *J Neurochem.* 1996; 66:1836–1844. [PubMed: 8780008]
- Hackenberg R, Hofmann J, Wolff G, Holzel F, Schulz KD. Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth. *J Cancer Res Clin Oncol.* 1990; 116:492–498. [PubMed: 2229140]
- He J, Evans CO, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Exp Neurol.* 2004a; 189:404–412. [PubMed: 15380490]
- He J, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. *Restor Neurol Neurosci.* 2004b; 22:19–31. [PubMed: 15096691]
- Hirvonen E. Progestins. *Maturitas.* 1996; 23(Suppl):S13–18. [PubMed: 8865133]
- Hoffman GE, Moore N, Fiskum G, Murphy AZ. Ovarian steroid modulation of seizure severity and hippocampal cell death after kainic acid treatment. *Exp Neurol.* 2003; 182:124–134. [PubMed: 12821382]
- Ibanez C, Shields SA, El-Etr M, Leonelli E, Magnaghi V, Li WW, Sim FJ, Baulieu EE, Melcangi RC, Schumacher M, Franklin RJ. Steroids and the reversal of age-associated changes in myelination and remyelination. *Prog Neurobiol.* 2003; 71:49–56. [PubMed: 14611867]
- Jayaraman A, Pike CJ. Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. *J Neuroendocrinol.* 2009; 21:77–81. [PubMed: 19094096]
- Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. *Brain Res.* 1996; 735:101–107. [PubMed: 8905174]
- Jodhka PK, Kaur P, Underwood W, Lydon JP, Singh M. The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression. *Endocrinology.* 2009; 150:3162–3168. [PubMed: 19325006]
- Junpeng M, Huang S, Qin S. Progesterone for acute traumatic brain injury. *Cochrane Database Syst Rev.* 2011:CD008409. [PubMed: 21249708]
- Kato J, Hirata S, Nozawa A, Yamada-Mouri N. Gene expression of progesterone receptor isoforms in the rat brain. *Horm Behav.* 1994; 28:454–463. [PubMed: 7729814]
- Kaur P, Jodhka PK, Underwood WA, Bowles CA, de Fiebre NC, de Fiebre CM, Singh M. Progesterone increases brain-derived neurotrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants. *J Neurosci Res.* 2007; 85:2441–2449. [PubMed: 17549730]
- Ke FC, Ramirez VD. Binding of progesterone to nerve cell membranes of rat brain using progesterone conjugated to 125I-bovine serum albumin as a ligand. *J Neurochem.* 1990; 54:467–472. [PubMed: 2299346]
- Koubovec D, Ronacher K, Stubrud E, Louw A, Hapgood JP. Synthetic progestins used in HRT have different glucocorticoid agonist properties. *Mol Cell Endocrinol.* 2005; 242:23–32. [PubMed: 16125839]

- Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S, Pfaff DW. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. *Proc Natl Acad Sci U S A*. 2000; 97:12816–12821. [PubMed: 11070092]
- Kumon Y, Kim SC, Tompkins P, Stevens A, Sakaki S, Loftus CM. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. *J Neurosurg*. 2000; 92:848–852. [PubMed: 10794300]
- Liu A, Margail I, Zhang S, Labombarda F, Coqueran B, Delespierre B, Liere P, Marchand-Leroux C, O'Malley BW, Lydon JP, De Nicola AF, Sitruk-Ware R, Mattern C, Plotkine M, Schumacher M, Guennoun R. Progesterone Receptors: A Key for Neuroprotection in Experimental Stroke. *Endocrinology*. 2012
- Liu L, Wang J, Zhao L, Nilsen J, McClure K, Wong K, Brinton RD. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. *Endocrinology*. 2009; 150:3186–3196. [PubMed: 19359388]
- Lorenz L, Dang J, Misiak M, Tameh Abolfazl A, Beyer C, Kipp M. Combined 17beta-oestradiol and progesterone treatment prevents neuronal cell injury in cortical but not midbrain neurones or neuroblastoma cells. *J Neuroendocrinol*. 2009; 21:841–849. [PubMed: 19686448]
- MacLusky NJ, McEwen BS. Progesterone receptors in rat brain: distribution and properties of cytoplasmic progesterone-binding sites. *Endocrinology*. 1980; 106:192–202. [PubMed: 6243096]
- Mannella P, Sanchez AM, Giretti MS, Genazzani AR, Simoncini T. Oestrogen and progestins differently prevent glutamate toxicity in cortical neurons depending on prior hormonal exposure via the induction of neural nitric oxide synthase. *Steroids*. 2009; 74:650–656. [PubMed: 19463685]
- Maurice T, Gregoire C, Espallergues J. Neuro(steroid) actions at the neuromodulatory sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection. *Pharmacol Biochem Behav*. 2006; 84:581–597. [PubMed: 16945406]
- McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. *Exp Gerontol*. 1994; 29:431–436. [PubMed: 7925761]
- Meffre D, Delespierre B, Guezou M, Leclerc P, Vinson GP, Schumacher M, Stein DG, Guennoun R. The membrane-associated progesterone-binding protein 25-Dx is expressed in brain regions involved in water homeostasis and is up-regulated after traumatic brain injury. *J Neurochem*. 2005; 93:1314–1326. [PubMed: 15934950]
- Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. *Eur J Biochem*. 1996; 239:726–731. [PubMed: 8774719]
- Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. *Embo J*. 1998; 17:2008–2018. [PubMed: 9524123]
- Min L, Takemori H, Nonaka Y, Katoh Y, Doi J, Horike N, Osamu H, Raza FS, Vinson GP, Okamoto M. Characterization of the adrenal-specific antigen IZA (inner zone antigen) and its role in the steroidogenesis. *Mol Cell Endocrinol*. 2004; 215:143–148. [PubMed: 15026187]
- Miyagawa K, Vidgoff J, Hermsmeyer K. Ca²⁺ release mechanism of primate drug-induced coronary vasospasm. *Am J Physiol*. 1997; 272:H2645–2654. [PubMed: 9227542]
- Morali G, Letchipia-Vallejo G, Lopez-Loeza E, Montes P, Hernandez-Morales L, Cervantes M. Post-ischemic administration of progesterone in rats exerts neuroprotective effects on the hippocampus. *Neurosci Lett*. 2005; 382:286–290. [PubMed: 15885907]
- Murphy DD, Segal M. Progesterone prevents estradiol-induced dendritic spine formation in cultured hippocampal neurons. *Neuroendocrinology*. 2000; 72:133–143. [PubMed: 11025407]
- Nilsen J, Brinton RD. Impact of progestins on estradiol potentiation of the glutamate calcium response. *Neuroreport*. 2002a; 13:825–830. [PubMed: 11997695]
- Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. *Endocrinology*. 2002b; 143:205–212. [PubMed: 11751611]

- Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. *Proc Natl Acad Sci U S A*. 2003; 100:10506–10511. [PubMed: 12925744]
- Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res*. 2005; 1049:112–119. [PubMed: 15932748]
- Robertson CL, Puskar A, Hoffman GE, Murphy AZ, Saraswati M, Fiskum G. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. *Exp Neurol*. 2006; 197:235–243. [PubMed: 16259981]
- Roof RL, Duvdevani R, Heyburn JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. *Exp Neurol*. 1996; 138:246–251. [PubMed: 8620923]
- Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. *J Neurotrauma*. 2000; 17:367–388. [PubMed: 10833057]
- Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. *Mol Chem Neuropathol*. 1997; 31:1–11. [PubMed: 9271001]
- Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol*. 2000; 36:2154–2159. [PubMed: 11127455]
- Rosario ER, Ramsden M, Pike CJ. Progestins inhibit the neuroprotective effects of estrogen in rat hippocampus. *Brain Res*. 2006; 1099:206–210. [PubMed: 16793026]
- Sakamoto H, Ukena K, Takemori H, Okamoto M, Kawata M, Tsutsui K. Expression and localization of 25-Dx, a membrane-associated putative progesterone-binding protein, in the developing Purkinje cell. *Neuroscience*. 2004; 126:325–334. [PubMed: 15207350]
- Sayed I, Parvez S, Wali B, Siemen D, Stein DG. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. *Brain Res*. 2009; 1263:165–173. [PubMed: 19368823]
- Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. *Maturitas*. 2003; 46(1):S7–S16. [PubMed: 14670641]
- Selmin O, Lucier GW, Clark GC, Tritscher AM, Vanden Heuvel JP, Gastel JA, Walker NJ, Sutter TR, Bell DA. Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. *Carcinogenesis*. 1996; 17:2609–2615. [PubMed: 9006096]
- Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V. Cloning and functional characterization of a sigma receptor from rat brain. *J Neurochem*. 1998; 70:922–931. [PubMed: 9489711]
- Singh M. Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. *Endocrine*. 2001; 14:407–415. [PubMed: 1144439]
- Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. *Endocrinology*. 1995; 136:2320–2324. [PubMed: 7720680]
- Sohrabji F, Miranda RC, Toran-Allerand CD. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. *Proc Natl Acad Sci U S A*. 1995; 92:11110–11114. [PubMed: 7479947]
- Stein DG. The case for progesterone. *Ann N Y Acad Sci*. 2005; 1052:152–169. [PubMed: 16024758]
- Strauss, J.; Barbieri, R. *Yen and Jaffe's Reproductive Endocrinology*. 5th edition. Saunders; 2004.
- Tanabe F, Miyasaka N, Kubota T, Aso T. Estrogen and progesterone improve scopolamine-induced impairment of spatial memory. *J Med Dent Sci*. 2004; 51:89–98. [PubMed: 15137470]
- Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. *Spine*. 1999; 24:2134–2138. [PubMed: 10543012]
- Tokmakov AA, Fukami Y. Nongenomic mechanisms of progesterone. *Tsitologiya*. 2009; 51:403–416. [PubMed: 19566032]

- Towle AC, Sze PY. Steroid binding to synaptic plasma membrane: differential binding of glucocorticoids and gonadal steroids. *J Steroid Biochem.* 1983; 18:135–143. [PubMed: 6843116]
- Vandromme M, Melton SM, Kerby JD. Progesterone in traumatic brain injury: time to move on to phase III trials. *Crit Care.* 2008; 12:153. [PubMed: 18522765]
- Vasan, R.; Vali, M.; Bell-Horner, C.; Kaur, P.; Dillon, GH.; Singh, M. Regulation of the GABA-A receptor by the MAPK pathway and progesterone. 33rd Annual Society for Neuroscience Meeting; New Orleans, LA. 2003. p. 472-412.
- Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. *Mol Endocrinol.* 1993; 7:1244–1255. [PubMed: 8264658]
- Vitarbo EA, Chatzipanteli K, Kinoshita K, Truettner JS, Alonso OF, Dietrich WD. Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. *Neurosurgery.* 2004; 55:416–424. discussion 424-415. [PubMed: 15271250]
- Wali B, Sayeed I, Stein DG. Improved behavioral outcomes after progesterone administration in aged male rats with traumatic brain injury. *Restor Neurol Neurosci.* 2011; 29:61–71. [PubMed: 21335669]
- Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. *Steroids.* 2003; 68:915–920. [PubMed: 14667983]
- Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. *J Comp Neurol.* 1993; 336:293–306. [PubMed: 8245220]
- Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. *Ann Emerg Med.* 2007; 49:402:391–402. e391–392. [PubMed: 17011666]
- Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. *Crit Care.* 2008; 12:R61. [PubMed: 18447940]
- Xu F, Plummer MR, Len GW, Nakazawa T, Yamamoto T, Black IB, Wu K. Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation. *Brain Res.* 2006; 1121:22–34. [PubMed: 17045972]
- Yao J, Chen S, Cadenas E, Brinton RD. Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons: antagonism by progesterone. *Brain Res.* 2011; 1379:2–10. [PubMed: 21134358]
- Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, Bramham CR. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. *J Neurosci.* 2002; 22:1532–1540. [PubMed: 11880483]
- Zhao Y, Wang J, Liu C, Jiang C, Zhao C, Zhu Z. Progesterone influences postischemic synaptogenesis in the CA1 region of the hippocampus in rats. *Synapse.* 2011; 65:880–891. [PubMed: 21308798]
- Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. *Proc Natl Acad Sci U S A.* 2003a; 100:2237–2242. [PubMed: 12601167]
- Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. *Proc Natl Acad Sci U S A.* 2003b; 100:2231–2236. [PubMed: 12574519]

Highlights of manuscript entitled, “Progesterone and Neuroprotection” (Authors: Singh and Su)

- Reviews the current state of knowledge on progesterone---induced neuroprotection
- Reviews the receptor pharmacology associated with progesterone---induced protection
- Reviews the signaling mechanisms that mediate progesterone---induced protection
- Defines key differences in the neurobiology of progesterone and MPA

Table 1

Comparison of the neuroprotection-relevant effects of progesterone and medroxyprogesterone acetate (MPA)

| Characteristic / Endpoint | Progesterone (P4) | MPA | Supporting reference(s) |
|---------------------------------|-------------------|--------------------|---|
| Binding to PR | Yes | Yes | Numerous references citing binding of P4 to PR. |
| Binding to AR | No | Yes | Hackenberg et al., 1990; Winneker et al., 2003; Schindler et al., 2003. |
| Binding to GR | No | Yes | Schindler et al., 2003; Koiubovec et al., 2005 |
| Neuroprotective | Yes | No | Roof et al., 1996, 1997; Nilson and Brinton, 2002a, 2003; Jodhka et al., 2009; and others (cited within this manuscript). |
| ERK1/2 phosphorylation | Yes | Yes | Singh, 2000; Nilson and Brinton, 2002a, 2003; Kaur et al., 2007 |
| Nuclear translocation of ERK1/2 | Yes | No | Nilson and Brinton, 2003 |
| Conversion to allopregnanolone | Yes | No | Numerous references support conversion of P4 to Allopreg. |
| Regulation of BDNF | Increase | No effect/decrease | Kaur et al., 2007; Jodhka et al., 2009 |

Abbreviations: MPA: medroxyprogesterone acetate; PR: progesterone receptor; AR: androgen receptor; GR: glucocorticoid receptor; ERK: extracellular-signal regulated kinase; P4: progesterone; BDNF: brain-derived neurotrophic factor.